Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience

Authors :: Nettis, Eustachio
Cegolon, Luca
Di Leo, Elisabetta
Canonica, Walter Giorgio
Detoraki, Aikaterini
Baiardini, I.
Bisaccia, M.
Cancian, M.
Capretti, S.
Colombo, G.
Conte, M.
Costantino, M.T.
D'Alò, S.
D'Angelo, A.
De Feo, G.
de Paulis, A.
Di Gioacchino, M.
Favero, E.
Fichera, S.
Gaeta, F.
Gangemi, S.
Gatta, A.
Heffler, E.
La Rosa, L.
Lodi Rizzini, F.
Macchia, D.
Macchia, L.
Maggi, E.
Martignago, A.
Minciullo, P.
Mineni, M.
Pannofino, A.
Parente, R.
Peveri, S.
Pucci, S.
Radice, A.
Ridolo, E.
Romano, A.
Rossi, O.
Savi, E.
Senna, G.E.
Senter, R.
Spadaro, G.
Stefanizzi, G.
Vacca, A.
Vignoli, A.
Villalta, D.R.
Yacoub, M.
Zaza, I.
Source :: Annals of Allergy, Asthma & Immunology; March 2018, Vol. 120 Issue: 3 p318-323, 6p
Publication Year :: 2018
Abstract: Omalizumab therapy is effective and safe in patients with chronic spontaneous urticaria (CSU) resistant to nonsedating histamine1(H1) antihistamines (nsAHs).

Full Text Access

Tools